We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA已批准首个PROTAC药物vepdegestrant（Veppanu）用于乳腺癌治疗。了解蛋白水解靶向嵌合体如何将疾病进展风险降低43%，并开启肿瘤学新时代。
